+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B



Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B



European Journal of Pharmacology 680(1-3): 8-15



Both mycelium and fruiting body of Antrodia camphorate, a traditional medicinal fungus of the family Polyporaceae in Taiwan, have been suggested to possess multiple biological functions. However, there is little information on the anticancer components and actions of mycelium of Antrodia camphorate. In the present study, the anticancer potential of synthesized maleimide derivatives, which have been isolated from mycelium of Antrodia camphorate, is examined. Comparing the cytotoxicity of two synthesized maleimide derivatives in four human cancer cell lines, camphorataimide B displayed potent efficacy. Then we investigated the impact of camphorataimide B on cell survival and cell cycle progression in vitro, and tumor growth in vivo in MDA-MB-231 breast cancer cells. Camphorataimide B decreased the cell viability and foci formation of MDA-MB-231 breast cancer cells. Further, camphorataimide B triggered apoptosis and blocked cell cycle progression of MDA-MB-231 breast cancer cells. Using immunoblotting analysis, camphorataimide B decrease the expression of cyclin-A and cyclin-B1. Moreover, we demonstrated for the first time that camphorataimide B inhibited cyclooxygenase-2 (COX-2) activity and protein expression in MDA-MB-231 cells. In nude mice study, camphorataimide B administration retarded the xenograft tumor growth of MDA-MB-231 cells. By immunohistochemical analysis, camphorataimide B decreased the expression of Ki-67 in xenograft tumor in vivo. It implied that camphorataimide B blocked cell cycle progression. Consistent with the cell culture investigation, camphorataimide B also reduced the expression of cyclin-A, cyclin-B1 and COX-2 in xenograft tumor. Thus, camphorataimide B may play a crucial role in prevention and therapy of malignant breast cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053865720

Download citation: RISBibTeXText

PMID: 22329896

DOI: 10.1016/j.ejphar.2012.01.032


Related references

Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Molecular Endocrinology 9(12): 1804-1813, 1995

Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin dependent kinase activity and decreased retinoblastoma protein phosphorylation. Breast Cancer Research & Treatment 37(Suppl. ): 81, 1996

Ectopic expression of PTEN negatively regulates both cell cycle progression and cell survival in breast cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting (41): 201, 2000

Effect of autophagy inhibition on cell viability and cell cycle progression in MDA‑MB‑231 human breast cancer cells. Molecular Medicine Reports 10(2): 625-630, 2014

The SMRT coregulator enhances growth of estrogen receptor-α-positive breast cancer cells by promotion of cell cycle progression and inhibition of apoptosis. Endocrinology 155(9): 3251-3261, 2014

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. Journal of Clinical Investigation 92(6): 2569-2576, 1993

Combined low-dose zearalenone and aflatoxin B1 on cell growth and cell-cycle progression in breast cancer MCF-7 cells. Toxicology Letters 281: 139-151, 2017

The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biology and Therapy 1(3): 256-262, 2002

Blockade of tumor cell transforming growth factor-bs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Experimental Cell Research 245(2): 0-9, 1998

Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Experimental Cell Research 245(2): 350-359, 1998

Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. Plos one 5(6): E11394, 2010

Lipid raft specific knockdown of SRC family kinase activity inhibits cell adhesion and cell cycle progression of breast cancer cells. Cancer Research 67(17): 8139-8148, 2007

Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Experimental Cell Research 234(2): 293-299, 1997

Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death. Experimental Cell Research 316(5): 800-812, 2010

Cyclooxygenase inhibitors block tumor growth, inhibit cell cycle and increase ceramide levels in a murine model of metastatic breast cancer. Proceedings of the American Association for Cancer Research Annual Meeting 43: 67, 2002